End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
51.17 CNY | -1.56% |
|
-1.25% | +4.11% |
Jul. 01 | Yunnan Baiyao Buys Rights on KA-1641 Drug | MT |
Jun. 12 | Yunnan Baiyao Group Co.,Ltd Announces Board Appointments | CI |
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+4.11% | 12.56B | C+ | ||
+54.07% | 809B | C+ | ||
+39.16% | 621B | B | ||
-7.05% | 351B | C+ | ||
+15.44% | 319B | B- | ||
+5.72% | 289B | C+ | ||
+14.26% | 238B | B+ | ||
-0.70% | 221B | A+ | ||
+14.60% | 218B | B- | ||
+7.42% | 166B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 000538 Stock
- Ratings Yunnan Baiyao Group Co.,Ltd